Please assess the completion status of the following clinical trial:

Trial Title: Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Men or women aged 18 to 75 years,~* Historically confirmed diagnosis of ulcerative colitis by endoscopy and histology,~* Patient being in remission, defined (according to Rachmilewitz) as:~Clinical Activity Index (CAI) \<= 4, and Endoscopic Index (EI) \< 4,~* Extent of inflammation during last acute episode was \>15 cm beyond the anal margin,~* Last acute episode ended within 3 months prior to study entry.~Exclusion Criteria:~* Crohn's disease,~* Prior bowel resection leading to diarrhoea,~* Toxic megacolon,~* Gastric or duodenal ulcer,~* Haemorrhagic diathesis,~* Presence of symptomatic organic disease of the gastrointestinal tract (with the exception of haemorrhoids or hiatal hernia),~* Active colorectal cancer or a history of colorectal cancer,~* Serious other secondary illnesses of an acute or chronic nature,~* Asthma,~* Severe impairment of renal (e.g., serum creatinine \> 1.5 mg/dl) and/or liver functions (e.g., serum transaminase \[ALT and/or AST\] or alkaline phosphatase \>=2x upper limit of normal \[ULN\]),~* Application of immunosuppressants within 3 months and/or corticosteroids (oral, intravenous \[IV\] or topical rectal) within 30 days prior to baseline,~* Application of non-steroidal anti-inflammatory drugs (NSAIDs) as long term treatment (i.e. \> 6 weeks), other than acetylsalicylic acid (\<= 350 mg/day), or paracetamol,~* Known intolerance/hypersensitivity to salicylic acid and its derivatives or to any of the other constituents of the study drugs,~* Well-founded doubt about the patient's cooperation,~* Existing or intended pregnancy, breast-feeding,~* Women of child-bearing potential without adequate contraceptive protection, e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide), partner has undergone vasectomy and subject is in monogamous relationship. The investigator is responsible for determining whether the subject has adequate birth control for study participation,~* Participation in another clinical trial within the last 30 days,simultaneous participation in another clinical trial, or previous participation in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 3.0g OD (Type: EXPERIMENTAL): None
- 1.5g OD (Type: EXPERIMENTAL): None
- 0.5g TID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).